Boldly transforming the lives of individuals with rare neurological diseases
Science-driven and patient-focused, our mission is to bring treatments to individuals with rare neurological diseases who have little or no treatment options.
Our deep understanding of human genetics and cellular function enables us to translate discoveries into meaningful therapies for rare neurological diseases.
At Ovid, we seek to understand what matters most to individuals with rare diseases and their families. We are committed to address the challenges they face every day.
- Ovid Therapeutics to Present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Conference
- Phase 2 ELEKTRA Study of Soticlestat (TAK-935/OV935) Meets Primary Endpoint Reducing Seizure Frequency in Children with Dravet Syndrome or Lennox-Gastaut Syndrome
- Ovid Therapeutics Announces Pricing of $50 Million Offering of Common Stock
- Ovid Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update